Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CorreGene MAGE-A1 TCR-T cell therapy
- Development stage
- Preclinical
- Lead developer
- CorreGene
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CorreGene MAGE-A1 TCR-T cell therapy is an investigational adoptive cell therapy being developed by CorreGene for the treatment of various solid tumors. The therapy involves engineering a patient's T cells to express a specific T-cell receptor (TCR) that targets the Melanoma-associated antigen A1 (MAGE-A1), a cancer-testis antigen frequently overexpressed in multiple malignancies but with limited expression in normal tissues. By recognizing MAGE-A1 peptides presented by Human Leukocyte Antigen (HLA) complexes, these modified T cells can specifically identify and eliminate tumor cells. The program is currently in the preclinical stage of development, aiming to provide a targeted immunotherapy option for patients with MAGE-A1-expressing tumors.
- Other names
- CorreGene MAGE-A1 TCR-TMAGE-A1 TCR-T cell therapyMAGE-A-1 TCR-T cell therapyMAGE-A 1 TCR-T cell therapy
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)
Beyond the preview
Go deeper on CorreGene MAGE-A1 TCR-T cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CorreGene MAGE-A1 TCR-T cell therapy.